https://www.usz.ch/forschung/Seiten/default.aspx  

8091 Zürich, Rämistrasse 100

The University Hospital Zurich is one of Switzerland’s largest hospitals and a pioneering institution in the field of clinical research. In its 40 departments and institutes, it assembles and practices all medical disciplines and enjoys an excellent reputation for state-of-the-art medicine, professional and com- passionate patient care, and groundbreaking bench-to-bedside translational medical research.

http://cdr-life.com/  

8810 Horgen, Tödistrasse 46

 info@cdr-life.com

CDR-Life is a Zurich-based biotech company that discovers and develops innovative medicines for the treatment of high need diseases. We invent and develop therapeutic antibody fragments with a focus on immuno-oncology and ophthalmology.

http://www.zueripharm.ch/  

8952 Schlieren, Südstrasse 3

 info@zueripharm.ch

As one of the leading hospital pharmaceutical competence centers in Switzerland, the hospital pharmacy of the University Hospital Zurich provides a wide range of services relating to therapeutic products at the highest possible level of quality and cost-effectiveness. In doing so, we are guided by the latest technologies and apply the most up-to-date pharmaceutical know-how.

https://glycoera.com/  

8820 Wädenswil, Einsiedlerstrasse 34

 +41 44 733 85 75
 info@glycoera.com

GlycoEra AG is advancing glycoengineered therapeutics to address unmet medical needs. Despite significant advancements in understanding the role of glycans in human health and diseases, this knowledge has not translated well into therapeutic drug development, a consequence of the limitations and complexities of controlling glycosylation processes. GlycoEra’s platform has overcome these challenges! The CustomGlycan Platform enables glycan-mediated modes of action through the engineering of highly defined specific glycan structures, accessing a novel combinatorial dimension for the treatment of very challenging diseases.

https://www.csl.com/we-are-csl/our-businesses-and-products/csl-vifor  

8952 Schlieren, Zürcherstrasse 39D

 +41 58 851 80 00

Pioneer in iron-based therapies, CSL Vifor is a global leader in iron deficiency and iron deficiency anaemia therapies, with a history dating back to 1872, when pharmacist Caspar Friedrich Hausmann opened a pharmacy in St. Gallen, Switzerland. Since then, we have proven our ability to identify and serve therapeutic areas and patients with significant unmet medical need. Building on our heritage and expertise in iron deficiency therapy, and together with our joint company Vifor Fresenius Medical Care Renal Pharma, today we have a strong and rapidly growing presence in nephrology, and we are committed to launching the next generation of therapies to truly address the full spectrum of kidney disease.

https://www.wysszurich.ch/projects/somagenetix  

8952 Schlieren, Wagistrasse 23

Gene therapy solutions for patients with severe inherited diseases.

https://www.roche.ch/en/sites/schlieren  

8952 Schlieren, Wagistrasse 10

 +41 43 215 10 00

The mission of the Roche Innovation Center Zurich (RICZ) is to be a leader in developing new generations of engineered antibody products with increased efficacy that address unmet clinical needs. The RICZ site is also the Center of Excellence in Cancer Immunotherapy within the Roche Group.

https://www.campus-schlieren.uzh.ch/en.html  

8952 Schlieren, Wagistrasse 12

The University of Zurich (UZH) is Switzerland’s largest university, with seven faculties and a current enrollment of over 26,000 students. More than 5,000 highly qualified members of the teaching staff, including some 580 professors, teach and conduct research at the 150 University institutes. In the field of life sciences, the University of Zurich is well known for its groundbreaking research in medicine, immunology, neuroscience, and structural biology. In the interest of serving the community, the University of Zurich promotes the transfer of research-based knowledge to private enterprise, and our spin-off ventures and business partnerships regularly lead to the creation of attractive jobs in innovative fields.